Pranav Mehta

@EquityValueIn Amazing clarity of thoughts!

Businesses I was reading this week , things that I read and heard that I found interesting across sectors, Market sense note 18/7/26 1) Triveni Engineering : Triveni Engineering & Industries Ltd. (TEIL) is executing a composite scheme of arrangement, sanctioned by the NCLT Allahabad Bench on 7 May 2026 and effective from 19 May 2026, that (a) amalgamates its 61.77%-owned sugar subsidiary Sir Shadi Lal Enterprises Ltd. (SSLEL) into TEIL, and (b) demerges the Power Transmission Business (PTB) — comprising the gears/gearbox and defence engineering undertakings — into a newly-created entity, Triveni Power Transmission Ltd. (TPTL). The demerger appointed date is 1 April 2026; the record date for share allotment has been fixed at 22 July 2026, with TPTL expected to list by end-August 2026. Our focus in this note is the PTB/TPTL leg of the transaction. This is the business that, in our view, the market has structurally under-priced inside the TEIL sugar-cyclical wrapper for over a decade — a pattern TEIL has walked before: the 2010 demerger of its steam turbine division into Triveni Turbine Ltd. (TTL) saw the spun-off entity go on to a ~30% share price CAGR over 15 years and a market cap (~Rs 18,000 cr) more than double that of the parent today. PTB is a 34-35% PBIT margin, OEM-approved, export-oriented gearbox and defence-engineering franchise with a Rs 340 crore capacity-expansion programme underway (Rs 231 cr already spent) that management guides can lift addressable capacity from ~Rs 400 cr to ~Rs 700 cr of revenue by September 2026, excluding the separate defence facility. • Record date 22 July 2026 for 1:3 TPTL share allotment (1 TPTL share of Rs 2 FV for every 3 TEIL shares of Re 1 FV held). • TPTL listing targeted by end-August 2026, subject to exchange approvals — the point at which PTB will, for the first time, be assigned a dedicated industrial-technology multiple by the market rather than a blended sugar-conglomerate multiple. • Capacity ramp to ~Rs 700 cr revenue potential by September 2026 (ex-defence facility), which is not yet reflected in trailing FY25/FY26 PTB financials. • Defence order momentum — an axial compressor test-gearbox order from a premier Indian defence establishment, described by management as one of the first such installations in Asia, is a credibility marker for further naval/aerospace opportunities. • Global OEM qualification: 11 new OEM customers added in 9M FY26 alone, against an approved-vendor list that already includes Siemens, MAN Energy Solutions, Mitsubishi, Atlas Copco and Doosan. • Management has articulated three durable moats: a manufacturing cost base 25-30% lower than European competitors; delivery lead times of 6-8 months versus 12+ months for EU peers; and an expanding global OEM-approved vendor list (Siemens, MAN Energy Solutions, Mitsubishi, Atlas Copco, Doosan, among others) built over the past two years, with 11 new OEM qualifications added in the first nine months of FY26 alone. Ahead of the demerger, TPTL acquired a Swiss subsidiary, Triveni Power Transmission GmbH, and opened a European sales office — both signal an intent to convert vendor-list access into recurring order flow from a base that has historically been concentrated in African export markets. Overall seems like a very interesting demerger an transaction to track , especially considering the capex going live in September and the tailwinds for a niche company in this space 2) CDMO : We have been tracking this space closely for a few years now and only believed one truth , capability + capacity + choice of what therapies not to be in , is what really drives companies in the right direction, why did Laurus win so big? Because they bet at the right time ahead of the curve , took the short term pain for the long term gain and change the trajectory of earnings Look at Wuxi AppTec in China for that context , the scale of their R&D , the focus on the tides portfolio and the ability to keep adapting and scaling is phenomenal , and why I bring this is up is not because I like the stock , but I like the intensity at which they operate , capture the value Chain , focus on the right modalities and take the risks with right Payoff’s , one company I really admire in this space , even though the stock is expensive and I don’t own it is Sai Life , they are really doing all the right things and most importantly focusing on the right variables for incremental growth , it is one of the business that in any major correction I will look to get interested in , because I see the depth there , I see what they are trying to build , it takes courage and patience , and they have a lot of it 3) Many times I think about decision making and the ability to keep playing the long game , it is all about challenging the idea of risk in your mind , re defining what big means to you and growing in character , I cannot be a great investor if I do not focus on building a good character , investing is a lot like life , we make hard decisions , wrong decisions and more but the idea of trusting the ability of the self , remember folks the market is like an ocean of returns , you choose if you want to pick up the water in a cup or tanker , but a play a big game , build a character that helps your survive the long game , and focus on always being open to learn , loose and flexible opinions often get rewarded in this business and strong ones get left behind Market sentiment check 1) Strong credit growth numbers are really helping private banks defend the lower price to book multiples, from flows front we are really having a better time than anytime in the last 2 years, the NIFTY outperformance to rest of EM has really started to show in July, yes, the others are up big last one year, but last month has started to show signs of strength in Indian markets 2) Good IPO’s reward sometimes , usually I don’t like IPO’s at all as I know most of them are trying to get listed at peak , but an Interesting one that I wrote on last week Laser power is doing really well , and two my surprise a second good IPO in the same 15 day period , Caliber Mining and Infra , a very interesting company at a reasonable valuation , something worth reading , will be releasing my note on this as well today 3) Biocon, Mylan stake sale was first indicated to be at discount , it ended up happening at 400 ( block sale ) and saw very strong participation , funds that didn’t get blocks even bought at10% higher , to be honest I am happy that we got our work done here on Yesintek aflibercept sales and overall thesis almost a month before it being a accepted thesis , now we have great margin of safety also , process wins when executed with discipline , now we just track the thesis as well and most importantly with Biocon , the execution ! 4) Lot of core coverage companies earnings start next week , so far earnings season seems to have started on a good note , too early to say , will be watching very closely to read between the lines and mapping where the delta is the largest in rate of change as well That's all for this one folks , hope you enjoyed reading this one , as result season starts , more companies where I see change starting will become a part of this list as well Disclaimer : none of the stocks mentioned are to be taken as financial advice in any form , this is not a recommendation , this is just my opinion based on public data and I may or may not be biased in few names , do not follow blindly !

Timepass talk on Sunday 1. Sudeep Pharma Sudeep Pharma is a manufacturer of excipients and specialty ingredients catering to the pharmaceutical, food, and nutrition industries. With a portfolio of more than 100 products, the company serves over 1,100 customers across 100 countries. What are excipients? Think of an excipient as the "delivery vehicle" or the supporting cast in a pharmaceutical formulation. While the Active Pharmaceutical Ingredient (API) is responsible for the therapeutic effect, it often constitutes only a small portion of a tablet or capsule. Excipients are the inactive ingredients, such as binders, fillers, stabilizers, and coatings, that provide the medicine with its structure, improve shelf life, enhance absorption, and ensure consistent delivery of the active drug. If you have been tracking the Indian pharma ancillary space closely, the word 'excipients' should immediately bring two more names to mind: Sigachi Industries and Accent Microcell. However, the structural economics of these businesses diverge completely based on their core chemistries. While Sigachi and Accent dominate the organic, cellulose-based excipient market (primarily Microcrystalline Cellulose), Sudeep Pharma operates in the inorganic, mineral-based excipient domain (Calcium and Magnesium salts). To put their operational moats into perspective: Cellulose-Based: Hard to engineer, but easier to qualify. Success depends on complex polymer physics and precision spray-drying, but the organic raw materials carry low regulatory risk. Mineral-Based: Easier to synthesize, but brutal to purify. The chemical reaction is textbook, but stripping out mined heavy metals down to safe parts-per-million (ppm) levels requires an elite purification infrastructure. We will leave it at that for now; a detailed forensic comparison of their manufacturing economics, margin profiles, and asset turns is a topic for another day! Coming back to Sudeep Pharma, they currently operates across two established verticals and is building a third growth engine. i) Pharmaceutical, Food & Nutrition (PFN): 56% of Revenue Under this segment, Sudeep manufactures high-purity mineral-based ingredients such as calcium, zinc, iron, potassium, magnesium, and sodium compounds. These ingredients are critical inputs for regulated pharmaceutical, nutraceutical, and food applications. The company is the first and only Indian manufacturer to receive USFDA approval for mineral-based ingredients, providing it with a strong competitive advantage in regulated markets. ii) Specialty Ingredients: 44% of Revenue The Specialty Ingredients division focuses on technology-driven, customized ingredient solutions designed to meet specific customer requirements. These products help improve nutritional delivery, enhance taste and texture, increase bioavailability, and ensure product stability across a variety of end-use applications. This is the company's higher-growth and higher-margin segment, benefiting from increasing customer demand for differentiated and value-added ingredient solutions. iii) Battery Materials: The Emerging Growth Driver Sudeep is making significant progress in battery-grade iron phosphate, a key raw material used in Lithium Iron Phosphate (LFP) batteries. The company expects to complete Phase-I of its battery materials project by the end of FY27, creating 25,000 TPA of capacity through an investment of approximately ₹300 crore. Management has outlined plans to invest a further ₹600 crore over the subsequent three years, taking total capacity to 100,000 TPA. Customer engagement appears encouraging. The company is already working with 42 global customers, and six of them have successfully completed commercial validation. Why are Q1FY27 margins expected to be under pressure? Phosphoric acid, one of the company's key raw materials, has witnessed a sharp increase in prices. While Sudeep has initiated price hikes to pass on these higher costs, certain customer contracts incorporate a lag before revised pricing becomes effective. As a result, Q1FY27 is likely to reflect only a partial benefit of the price increases, leading to temporary margin compression. Management expects margins to normalize from Q2FY27 onwards as the full impact of the price pass-through is realized. 2. Divgi Torq Transfer Systems Divgi-TTS is a premier Indian automotive component manufacturer specializing in advanced drivetrain solutions, including engineered transfer cases, torque couplers, and transmission systems. It positions itself as an independent, high-tech player at the forefront of the automotive industry's structural shift toward electric vehicles (EV), dual-clutch transmissions (DCT), and advanced four-wheel-drive (4WD) systems. After a prolonged slowdown, Divgi is entering a strong structural turnaround driven by a sharp recovery across its core verticals and an aggressive expansion into global markets The Near-Term Trajectory (FY27): Financial growth is highly visible, anchored by a lucrative, exclusive one-time Indonesian government export order for 70,000 transfer cases. Split equally through its key domestic OEM partners, Mahindra & Mahindra and Tata Motors, this single program is projected to deliver an incremental ₹170–180 crore in revenue for FY27. The Long-Term Sustainability (FY28 & Beyond): To counter the cyclical cliff of the one-time Indonesian order, management is scaling multiple independent, multi-year growth triggers. These include upcoming vehicle platforms like the Tata Sierra 4WD program, increased export volumes to the US via a Ford-related application, and entry into the high-volume electric 3-wheeler segment. Furthermore, its EV transmission vertical is poised to capture underpenetrated market share as newly approved proprietary designs ramp up for Tata Motors' Nexon and Curvv EV platforms. 3. Anthem Biosciences Anthem Biosciences is a fully integrated CRDMO with capabilities spanning the entire drug discovery, development, and manufacturing value chain. It is among the few Indian companies offering services across both New Chemical Entity (NCE) and New Biological Entity (NBE) programs. Over the years, the company has built expertise across several advanced technology platforms, including RNA interference (RNAi), Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides. The CRDMO segment contributes over 80% of Anthem’s revenues and enjoys industry-leading profitability. EBITDA margins stood at 43.4% for FY26 and expanded to 48.1% in Q4 FY26. No other listed Indian CRDMO operates at a comparable margin profile. Management attributes these margins to structural advantages arising from backward integration, process efficiencies, and disciplined cost control rather than any one-off benefit. Rimegepant, the active ingredient in Pfizer’s blockbuster migraine therapy Nurtec ODT, is estimated to contribute nearly 20–25% of Anthem’s CRDMO revenues. With Nurtec generating more than $1.4 billion in sales during 2025, Rimegepant remains one of Anthem’s most commercially significant molecules. Anthem is currently undertaking the largest capacity expansion program in its history. The company also added two new global Big Pharma customers during FY26, further strengthening its client base. Over the last two to three quarters, Anthem commercialized four new molecules, taking its portfolio of globally commercialized products to 14. For each of these molecules, Anthem serves as the sole-source manufacturer of either the final Active Pharmaceutical Ingredient (API) or a critical regulatory intermediate. External analysts estimate that the peak global commercial opportunity associated with the four newly commercialized molecules is approximately $10 billion. In addition, Anthem currently has 10 molecules in Phase III clinical trials, providing a strong foundation for future commercial launches and long-term growth. That said, valuations are screamingly expensive at this point. 4. The WuXi AppTec Euphoria The news that the Pentagon has added WuXi AppTec to its list of companies allegedly linked to the Chinese military dominated discussions across financial Twitter this week. However, much of the broader narrative appears either misplaced or misunderstood. i) What happened? The Pentagon updated its annual 1260H list, adding roughly two dozen entities, including high-profile Chinese companies such as Alibaba, Baidu, BYD, and WuXi AppTec, one of the world's largest CRDMO players. The 1260H designation identifies companies that the U.S. government believes are either assisting China's People's Liberation Army (PLA) or are linked to Beijing's military-civil fusion strategy. WuXi AppTec responded immediately, calling the designation "clearly a mistake" and reiterating that it is neither controlled by nor affiliated with any military or government entity, nor does it provide services to China's armed forces. ii) How significant is WuXi's U.S. exposure? Very significant. Approximately 75% of WuXi AppTec's revenues are derived from U.S. customers. Sell-side analysts, including Bloomberg Intelligence, estimate that as much as $30.4 billion (206 billion yuan) of U.S.-linked revenue could be at risk between 2027 and 2030 if customers aggressively diversify away from the company. iii) Does this mean U.S. pharma companies will stop working with WuXi immediately? The simple answer is no. The 1260H designation itself does not impose immediate sanctions, asset freezes, or commercial restrictions. However, it gains significance through its interaction with the Biosecure Act, which was signed into law in December. The legislation restricts U.S. government agencies from contracting with organizations that rely on services provided by companies appearing on the Pentagon's Chinese military companies list. Importantly, the framework includes a five-year grandfathering period, allowing existing pharmaceutical clients sufficient time to wind down contracts, transfer manufacturing processes, and establish alternative supply chains without jeopardizing eligibility for federal healthcare programs such as Medicare and Medicaid. There is another important nuance. The restriction primarily applies to federally funded programs. If a pharmaceutical company operates both federally funded and privately funded projects, only the government-funded programs face direct compliance challenges. While maintaining separate supply chains introduces significant regulatory complexity and compliance costs, private commercial programs can technically continue working with WuXi. iv) WuXi's reshoring strategy WuXi is not standing still. WuXi AppTec continues to expand its Delaware manufacturing footprint, with the objective of locating roughly 20-30% of its global capacity within the United States. Similarly, WuXi Biologics is relocating an estimated 30-40% of its capacity to U.S. facilities in an effort to mitigate future cross-border restrictions and reassure customers. v) So, are Indian CDMOs immediate beneficiaries? Not necessarily in the short term. This development is unlikely to create an overnight revenue windfall for Indian CRDMOs. However, it does accelerate a trend that was already underway: supply-chain diversification away from China. As large pharmaceutical companies reassess long-term manufacturing dependencies, Indian CRDMOs are likely to become key beneficiaries of incremental outsourcing mandates. The opportunity is less about immediate contract transfers and more about becoming part of the next-generation global supply chain architecture. For example, Eli Lilly maintains substantial exposure to Chinese manufacturing partners but already works with companies such as Divi's Laboratories and Sai Life Sciences. The ongoing WuXi situation could encourage Lilly to gradually increase sourcing from Indian partners as part of a broader risk-mitigation strategy. Similar dynamics could play out across several large U.S. pharmaceutical companies, including Pfizer and others. The key takeaway is that the WuXi episode is not an overnight revenue event for Indian CDMOs. It is, however, another catalyst pushing global pharma companies toward geographic diversification, and India remains one of the most credible alternatives available at scale. 5. Aegis Logistics Aegis Logistics is one of India's leading logistics and supply-chain companies, specializing in the storage, handling, and distribution of clean energy products such as liquefied petroleum gas (LPG), ammonia, and liquid chemicals. The company operates a strategically located network of cryogenic and liquid storage terminals across major ports on both the western and eastern coasts of India. Why the excitement? Recent geopolitical developments and volatility in global energy markets have highlighted Aegis' unique business model. Through its VLGC-compliant infrastructure, extensive import capabilities, and strong global partnerships, the company can source LPG from the most economical global markets rather than being dependent on a single region. This flexibility enables Aegis to expand distribution margins during periods of supply disruption and price dislocation, turning market volatility into a competitive advantage. That said, the bigger story is not the short-term opportunity, it is the long-term infrastructure platform that Aegis is building. i) Significant Commissioning of Growth CapEx Aegis is entering a phase where several large projects are expected to begin contributing simultaneously. Liquid Storage Expansion The first phase of a ₹1,675 crore expansion project at JNPT, comprising approximately 318,100 cubic meters of additional liquid storage capacity, is scheduled for commissioning in H1 FY27. In parallel, the Mumbai terminal will add another 64,000 kiloliters of liquid storage capacity during the same period. Integrated Pipavav Ecosystem Pipavav is evolving into a fully integrated LPG logistics hub. The new VLGC-compliant jetty is expected to be commissioned during CY2026, while the associated pipeline connectivity is scheduled to become operational in Q2 FY27. Full-Year Asset Contribution Cryogenic infrastructure commissioned at Pipavav and Mangalore during FY26 operated only for part of the year. FY27 will be the first year in which these assets contribute for the full twelve months. ii) Multi-Modal Connectivity to Unlock Higher Throughput For any terminal operator, storage capacity is only one side of the equation. The speed at which products can be evacuated determines overall throughput and asset utilization. Several key connectivity projects are expected to come online during FY27: The Jamnagar-Loni pipeline connection at Kandla has already been completed. The Kandla-Gorakhpur LPG Pipeline (KGPL) is expected to connect Kandla in H1 FY27 and Pipavav in Q2 FY27. New LPG rail gantries are under construction at both Mangalore and Pipavav, creating efficient and cost-effective evacuation routes into Central, Southern, and Western India. These projects should significantly improve terminal utilization and throughput volumes across the network. iii) Scaling the High-Margin Gas Distribution Business Historically, Aegis' gas distribution operations were concentrated primarily around Mumbai and Kandla. Over the past few years, the company has transformed into a multi-regional platform with operations spanning Mangalore, Haldia, Pipavav, and other strategic locations. Supported by this expanded infrastructure footprint, management is targeting a substantial increase in distribution volumes, with an ambition to reach approximately 2 million tonnes by FY28. As distribution volumes scale over a largely fixed infrastructure base, operating leverage could become an increasingly important earnings driver. iv) Early-Mover Advantage in India's Emerging Ammonia Economy Aegis is also positioning itself to participate in India's evolving ammonia and clean-energy value chain. The company is developing India's first independent ammonia terminal at Pipavav, with a static storage capacity of 36,000 metric tonnes. The project is expected to be commissioned in H1 FY27. Importantly, approximately one-third of the terminal's capacity is already backed by a 15-year take-or-pay agreement with Hindustan Zinc, providing strong revenue visibility from day one. The remaining capacity will be available for third-party customers, creating opportunities for higher-margin throughput and distribution revenue. The long-term opportunity could be substantial. CRISIL estimates that India could face an ammonia supply-demand gap of nearly 3 million tonnes by 2029. Through its strategic partnership with ITOCHU Corporation, which has acquired a stake in the Pipavav ammonia terminal, Aegis is positioning itself at the center of this emerging opportunity. v) The Bigger Picture Aegis Logistics is gradually transforming from a traditional storage terminal operator into a diversified clean-energy logistics platform. Between large-scale capacity additions, improving pipeline and rail connectivity, a rapidly expanding gas distribution business, and a first-mover position in ammonia infrastructure, the company appears to be entering a period where multiple growth drivers could begin contributing simultaneously over the next two to three years. That's all for this edition. Have a great Sunday! Disclaimer: None or buy or sell recommendations. This publicly available information is shared for learning and education purposes.

Chart of the week #ADANIPOWER is one of most powerful charts I have seen in a while. If you have permissions to trade BSE, then I highly recommend you follow my friend Aksel Kibar @TechCharts who is "plugged in" on this stock #price" target="_blank" rel="nofollow noopener">blog.techcharts.net/sign-up/#price

What an achievement. Very few people talk about this. But this is massive. Power sector reforms have worked wonders. The government(s) must be congratulated for this. @MinOfPower How this was achieved. 1. The "Late Payment Surcharge" (LPS) Rules, 2022The government notified the Electricity (Late Payment Surcharge and Related Matters) Rules, 2022 on June 3, 2022. This created a strict legal framework that: Frozen Arrears: Classified all outstanding dues up to that date as "legacy arrears." EMI System: Mandated that these arrears be rescheduled into Equated Monthly Installments (EMIs). As of February 2026, utilities have successfully paid 43 EMIs, with some even pre-paying their debts. 2. Enforcement through the PRAAPTI PortalThe PRAAPTI (Payment Ratification and Analysis in Power Procurement for bringing Transparency in Invoicing of generators) portal was used to monitor payments in real-time. If a DISCOM fails to pay an EMI or current dues, the rules allow for the regulation of power supply, meaning their access to short-term power markets can be restricted. This "stick" approach enforced financial discipline. 3. Structural Reform Schemes (UDAY & RDSS) UDAY (Ujwal DISCOM Assurance Yojana): Focused on financial restructuring and reducing operational losses (AT&C losses). RDSS (Revamped Distribution Sector Scheme): Launched in 2021 with a ₹2.83 lakh crore outlay. Funding is performance-linked, meaning states only receive money if they meet specific targets for loss reduction and smart metering.

What if all of physics emerges from consistency between local observers? That’s the core idea behind Observer Patch Holography (OPH). This 20-chapter book explains reality from the ground up to the emergence of space, time and particles. oph-book.floatingpragma.io/landing

There's one undisputed king of slides: Masayoshi Son at SoftBank. Here are some of his greatest hits 🧵 1. "Hypothetical Illustration of EBITDA", an all-time classic:

29th ANNUAL WEALTH CREATION STUDY (2019-2024) Creating Wealth Through Bruised Blue Chips Wealth Creation in the last 5 years is the highest ever; Wealth Destruction is among the lowest Key Highlights in a Thread🧵 REPOST & BOOKMARK😄 Let’s Go!🥳

If you don't know how to code, but want to take advantage of AI to code, learn: - Math up to algebra - Statistics and probability - Data structures and algorithms - Game theory - Fundamental programming concepts (variables, loops, conditionals) - How to break down problems into smaller steps - Version control (e.g. Git) - SQL - HTML/CSS for web structure, styling - How HTTP requests and the web works

#Q1FY25 Results Summary💹 Sectors which did well🔖 - Capital Markets - Recycling - Pharma - Generic, API, CDMO - Auto/Auto Ancillaries - Real Estate - EMS - EPC, Renewables, Solar Pumps - Power & Proxy - T&D , W&C, Transformer - Consumer Durables - Textiles - Alcoholic Beverages - Retailers - IT/Platform/SAAS - Packaging Film/ Dairy - Agro Chemicals/Chemicals - Financials - Housing Finance, Select NBFC #investing #stockmarkets #StocksToWatch

78 Pharma companies had a #Q1FY25 Aggregate Revenue growth of +10% YoY to ~₹99K Cr & EBITDA growth of +24% YoY to ~₹24K Cr. Aggregate Gross Margin improved by +248bps YoY which translated to EBITDA margin expansion of ~174bps YoY Domestic Focused Indian Pharma Co.s. showcased best YoY performance in terms of Revenue growth and operating profitability. #Health2Wealth #Perpetuity

Took different strategic positions to check which setups are working well in the current market conditions All three setups are doing very good .. Earnings bases, High tight flags and institutional push out bases

Wonderful video by @prachyam7 explaining about the recent bangladesh coup & anti hindu riots Please share widely

𝗔𝗰𝗲 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗔𝘀𝗵𝗶𝘀𝗵 𝗞𝗮𝗰𝗵𝗼𝗹𝗶𝗮'𝘀 𝘀𝘁𝗼𝗰𝗸𝘀 His networth is over Rs 3273 Crores 🔥 ⭐ Top 10 Undervalued Smallcaps in his portfolio A Mega [Thread ] 🧵 10 Multibaggers below 👇

What is a short nonfiction book that is an excellent read? For example: Manual for Living by Epictetus The Lessons of History by Durant A Mathematician’s Apology by Hardy What else?

This is Professor David Sinclair He is 53 years old but looks like he's in his 20s He is a Harvard Genetics Professor and this are his secrets to reverse ageing: 1. Exercise to the point of losing your breath

Below is a link to a document called the Gannon Compilation, where I centralized Geoff's writings from 2005 to the present in one easy-to-navigate file. 2,725 pages and 1,200,526 words going back almost 20 years. 👇👇 bit.ly/3BVVoUK

#ArcheanChemicals - They plan to enter semi conductors space as per the below article through their subsidiary. If goes through, would be a BIG KICKER to their valuations....! BNK also came out with a coverage 10 days back 👍

Protean e-Gov Tech is a Rs.5000 cr mkt cap entity with perhaps the best of all the worlds. What's on offer? A leader in Digital Public Infra. @DamaniAshok (as always) has come up with an apt 4 pager which encapsulates all that makes @ProteanEgovTech a compelling story.